• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Lower AMVUTTRA Guidance Altering The Investment Case For Alnylam Stock?

    Simply Wall St·10/21/2026 05:34:49
    语音播报
    • Alnylam Pharmaceuticals recently reported record AMVUTTRA revenue tied to its ATTR cardiomyopathy indication, while also cutting full year guidance as demand patterns settled after the initial launch surge and competition around the franchise intensified.
    • The combination of sustainable profitability and potential S&P 500 eligibility now sits alongside a more cautious AMVUTTRA outlook, which puts execution on pricing, access and competitive differentiation at the center of Alnylam Pharmaceuticals' operating story.
    • Next comes a look at how Alnylam Pharmaceuticals' investment narrative shifts when AMVUTTRA guidance is reduced even as the ATTR franchise scales.

    Scan how other profitable healthcare names are priced for execution risk and competition by comparing Alnylam Pharmaceuticals with a hand-picked list of 37 healthcare AI stocks.

    Alnylam Pharmaceuticals Investment Narrative Recap

    To own Alnylam Pharmaceuticals, you need to believe the RNAi platform can keep producing commercially meaningful products while the ATTR franchise matures. The short term story still leans heavily on AMVUTTRA and its cardiomyopathy use, even after management cut guidance as early demand patterns cooled and rival options started to influence prescribing.

    The clearest near term catalyst is management execution on pricing and access that keeps AMVUTTRA volumes healthy without eroding net revenue per patient. The main risk is further pressure on TTR guidance, whether from payer pushback, deeper net price erosion or slower than expected uptake, which would quickly feed through to earnings sensitivity.

    Recent commentary around sustainable profitability and potential S&P 500 eligibility is the announcement that now matters most for this news. It confirms Alnylam Pharmaceuticals has shifted from a pure pipeline story to a business that is already generating US$4.8b of annual revenue and US$774.7m of net income while investors reassess AMVUTTRA expectations.

    If AMVUTTRA trends stay within the lowered guidance range, index eligibility can keep attention on execution rather than just the guidance reset. If TTR revenue or margin pressure accelerates, focus likely swings back to whether the broader RNAi pipeline, including programs like zilebesiran and nucresiran, can offset any hit to ATTR driven cash generation.

    Alnylam Pharmaceuticals' narrative projects US$8.8b revenue and US$1.7b earnings by 2029. That path assumes revenue grows at 22.4% a year and earnings rise by about US$925m from US$774.7m today.

    Uncover why Alnylam Pharmaceuticals' fair value indicates a 61% potential upside to its current price that could close faster than you expect.

    NasdaqGS:ALNY 1-Year Stock Price Chart
    NasdaqGS:ALNY 1-Year Stock Price Chart

    Exploring Other Perspectives

    One optimistic twist you might explore is how bullish analysts frame zilebesiran. Before this guidance reset, the highest forecasts were built around revenue reaching about US$11.1b and earnings of US$2.7b by 2029, assuming hypertension trials reshaped the story. That view could shift as you weigh this new AMVUTTRA update.

    Explore 4 other Alnylam Pharmaceuticals fair value estimates, including one that suggests as much as 180% upside from the current price!

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Alnylam Pharmaceuticals?

    If you want to pressure test your view on Alnylam Pharmaceuticals, it helps to see how other companies with different profiles are priced on Simply Wall St.